Study Finds 1.2 Million Daily Cannabis Users in Great Britain

The headline number and what it measures

A study reported by Yahoo on Nov. 14, 2026 puts daily cannabis use in Great Britain at roughly 1.2 million people. The figure covers England, Scotland and Wales, not the whole United Kingdom.

Geographic scope matters here. Northern Ireland sits outside the "Great Britain" label, so the number can't be read as a UK-wide total.

All CannIntel has to work with is a headline and a syndication link. It doesn't include the study's authors, publishing institution, sample size, survey dates or methodology. We haven't independently verified those details, so we've left them out.

Why daily use is the metric to watch

Daily use is a different public-health and policy category than past-year or past-month use. Regulators in legal markets tend to treat frequent consumption as the segment most associated with dependence risk and the heaviest product demand.

For operators, daily users drive a disproportionate share of volume wherever legal sales exist. In the UK, that demand is currently met outside any licensed retail channel.

One caution: "daily use" definitions vary by survey. Some count any use on each day of a reference period, while others set a threshold of 20 or more days a month. Without the study's definition, the 1.2 million figure is hard to compare against other datasets.

The legal backdrop in Great Britain

Cannabis remains a controlled substance in the UK, with recreational possession and supply criminalized. Under the Misuse of Drugs Act 1971, cannabis is classed as a Class B drug.

Medicinal access has existed since November 2018, when the Misuse of Drugs (Amendment) (Cannabis and Licensed Products) Regulations 2018 allowed specialist doctors to prescribe certain cannabis-based products. NHS access has stayed extremely limited, and most patients use private clinics.

Set 1.2 million daily users against that framework and the gap is plain. The distance between consumption and legal supply is the story.

The medical-versus-recreational gray zone

Some portion of daily users likely obtain cannabis through the private prescription route, but the study as reported doesn't say how many. That split is the key unknown.

If a meaningful share of daily users are patients, the data points to unmet medical demand. If most are recreational consumers buying on the illicit market, it points to a different policy conversation about enforcement and harm reduction.

Both readings are plausible. Neither can be confirmed from the headline alone.

What this means for operators and investors

Daily-use counts are the raw material for market-sizing models, which is why this figure will get cited. Analysts building UK demand scenarios typically start from prevalence data and layer on assumptions about spend per user.

The caveats are significant:

• No legal adult-use market exists, so any revenue projection is hypothetical.
• Survey self-reporting can understate or overstate use, depending on stigma and methodology.
• Great Britain excludes Northern Ireland, so UK totals would run higher.

This isn't a market. It's a baseline, and a useful one only once the methodology is public.

The policy question this feeds

Prevalence data like this tends to surface in debates over decriminalization, regulation and policing priorities. Advocates cite high use as evidence that prohibition isn't suppressing demand. Opponents cite it as evidence of a public-health burden.

The numbers don't settle that argument. They just hand both sides a fresh talking point.

For full background on how consumption data is shaping the debate, see the CannIntel topic hub on UK cannabis use trends.

What we still don't know

Key details about the study's origin and design are unconfirmed in the available signal. Until they're public, treat the 1.2 million estimate as a headline figure rather than a settled count.

Items to confirm when the underlying report is located:

1. The publishing body and lead researchers
2. The survey period and sample size
3. How "daily use" was defined
4. Whether the estimate carries a confidence interval
5. Any breakdown by age, region or medical status

Not yet. That's where this stands. The next signal to watch is publication of the underlying report, which would show who ran the study, how it defined daily use and whether the 1.2 million figure holds up.